Business Context and Reporting Period
This Form 8-K filing by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) covers events occurring on December 18, 2019, with the report dated December 20, 2019. The company, incorporated in Nevada and trading on the Nasdaq Capital Market under the symbol EKSO, announced the completion of a registered direct offering of common stock and warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $5.0 million from the sale of 11,111,116 shares of common stock and related warrants.
- Net Proceeds: Approximately $4.4 million after fees and expenses.
- Offering Price: $0.45 per share and related warrant.
- Warrant Terms: 8,333,337 warrants issued with an exercise price of $0.5402 per share, exercisable six months and one day after issuance, expiring five years thereafter.
- Placement Agent Fees: Total cash fees of approximately $450,000 (7.0% cash fee plus 1.0% management fee) plus reimbursement of $95,000 in expenses.
- Placement Agent Warrants: 777,778 warrants issued to the placement agent with an exercise price of $0.5625.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement for the registered direct offering. The agreement includes a 45-day lock-up period prohibiting the company from selling common stock or convertible securities, with exceptions for a previously announced joint venture in China (the "China JV Arrangement") and an at-the-market facility after the 45-day period. Additionally, the company is restricted for one year from issuing securities with prices that vary based on the trading price of the common stock or are reset based on future events, subject to the same exceptions.
Outlook, Risks, and Unusual Items
Anti-Dilution Adjustment: The filing discloses a material adjustment to existing warrants issued in May 2019. Due to the offering price of $0.45 being lower than the previous exercise price of $2.00, the exercise price of 6,666,667 existing warrants will be reduced. The new price will be the lower of $0.45 or the lowest one-day volume-weighted average price of the common stock during the five trading days starting December 19, 2019.
Use of Proceeds: The filing does not specify the exact allocation of the net proceeds beyond general corporate purposes implied by the offering structure.
Investor Verification Checklist
- Verify the final adjusted exercise price of the May 2019 warrants based on the five-day volume-weighted average price calculation.
- Confirm the status and terms of the "China JV Arrangement" referenced as an exception to the lock-up provisions.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Monitor the company's cash position post-closing to assess liquidity relative to operating expenses.